Integrins as therapeutic targets

Trends in Pharmacological Sciences

Volumn 33, Issue 7, 2012, Pages 405-412

  Goodman, Simon L ^a   Picard, Martin ^a  

^a MERCK KGAA   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 [4 [AMINO(ETHOXYCARBONYLIMINO)METHYL]PHENYL] 2 THIAZOLYL](1 ETHOXYCARBONYLMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID ETHYL ESTER; 4 (4 AMIDINOPHENOXY)BUTYRYLASPARTYLVALINE; ABCIXIMAB; ACETYLCYSTEINYLASPARAGINYL 5,5 DIMETHYLTHIOPROLYL 4 AMINOMETHYLPHENYLALANYLGLYCYLASPARTYLCYSTEINE; AH 111585; ALNIDOFIBATIDE; BG 00002; CILENGITIDE; CLOTINAB; CS 511; EFALIZUMAB; ELAROFIBAN; EMD 85189; EOS 200 4; EPTIFIBATIDE; ETARACIZUMAB; ETROLIZUMAB; FIBRINOGEN RECEPTOR; FIRATEGRAST; FLUCICLATIDE F 18; GE 135; INTEGRIN; INTETUMUMAB; LEFRADAFIBAN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MED 522; MK 0852; N ACETYLPROLYLHISTIDYLSERYLCYSTEINYLASPARAGINE AMIDE; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; NATALIZUMAB; NSC 707544; ODULIMOMAB; ORBOFIBAN; RG 7413; ROVELIZUMAB; TIROFIBAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDOLIZUMAB; VERY LATE ACTIVATION ANTIGEN 4; VITRONECTIN RECEPTOR; VOLOCIXIMAB;

ACUTE CORONARY SYNDROME; ANTINEOPLASTIC ACTIVITY; ARTHRITIS; BRAIN ISCHEMIA; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; CELL ADHESION; COLORECTAL CANCER; CORONARY ARTERY DISEASE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EXTRACELLULAR MATRIX; GLIOBLASTOMA; GLIOMA; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK TUMOR; HEART MUSCLE ISCHEMIA; HUMAN; IMMUNE DEFICIENCY; KIDNEY CANCER; LEIOMYOSARCOMA; LIGAND BINDING; LUNG NON SMALL CELL CANCER; MELANOMA; METASTATIC MELANOMA; MULTIPLE SCLEROSIS; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPOROSIS; OVARY CANCER; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROSTATE CANCER; PSORIASIS; RESTENOSIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; THROMBOSIS; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL COMMUNICATION; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DESIGN; HUMANS; INTEGRINS; LIGANDS;

EID: 84862686491     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.04.002     Document Type: Review

References (73)

1. Hynes, R.O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110, 673-687
2. Schwartz, M.A. and Ginsberg, M.H. (2002) Networks and crosstalk: integrin signalling spreads. Nat. Cell Biol. 4, E65-E68
3. Shattil, S.J. et al. (2010) The final steps of integrin activation: the end game. Nat. Rev. Mol. Cell Biol. 11, 288-300
4. Somanath, P.R. et al. (2009) Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 12, 177-185
5. Margadant, C. and Sonnenberg, A. (2010) Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep. 11, 97-105
6. Zutter, M.M. (2007) Integrin-mediated adhesion: tipping the balance between chemosensitivity and chemoresistance. Adv. Exp. Med. Biol. 608, 87-100
7. Hodkinson, P.S. et al. (2006) ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 13, 1776-1788
8. Caswell, P.T. et al. (2009) Integrins: masters and slaves of endocytic transport. Nat. Rev. Mol. Cell Biol. 10, 843-853
9. Barczyk, M. et al. (2010) Integrins. Cell Tissue Res. 339, 269-280
10. Ruoslahti, E. and Pierschbacher, M.D. (1987) New perspectives in cell adhesion: RGD and integrins. Science 238, 491-497
11. Arnaout, M.A. et al. (2007) Structure and mechanics of integrin-based cell adhesion. Curr. Opin. Cell Biol. 19, 495-507
12. Millard, M. et al. (2011) Integrin targeted therapeutics. Theranostics 1, 154-188
13. Cox, D. et al. (2010) Integrins as therapeutic targets: lessons and opportunities. Nat. Rev. Drug Discov. 9, 804-820
14. Legate, K.R. and Fässler, R. (2009) Mechanisms that regulate adaptor binding to b-integrin cytoplasmic tails. J. Cell Sci. 122, 187-198
15. Kinashi, T. (2012) Overview of integrin signaling in the immune system. Methods Mol. Biol. 757, 261-278
16. Villablanca, E.J. et al. (2011) Blocking lymphocyte localization to the gastrointestinal mucosa as a therapeutic strategy for inflammatory bowel diseases. Gastroenterology 140, 1776-1784
17. Stefanich, E.G. et al. (2011) A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. Br. J. Pharmacol. 162, 1855-1870
18. Pucci, E. et al. (2011) Natalizumab for relapsing remitting multiple sclerosis. Cochrane Database Syst. Rev. CD007621
19. Major, E.O. (2010) Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu. Rev. Med. 61, 35-47
20. Arthos, J. et al. (2008) HIV-1 envelope protein binds to and signals through integrin α4β7, the gut mucosal homing receptor for peripheral T cells. Nat. Immunol. 9, 301-309
21. Frampton, J.E. and Plosker, G.L. (2009) Efalizumab: a review of its use in the management of chronic moderate-to-severe plaque psoriasis. Am. J. Clin. Dermatol. 10, 51-72
22. Rao, V.R. et al. (2010) Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR). Invest. Ophthalmol. Vis. Sci. 51, 5198-5204
23. Coller, B.S. and Shattil, S.J. (2008) The GPIIb/IIIa (integrin αIIbβ3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 112, 3011-3025
24. King, A. (2010) Eptifibatide is noninferior to abciximab: implications for clinical practice. Nat. Rev. Cardiol. 7, 539
25. Hartman, G.D. et al. (1992) Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35, 4640-4642
26. Cox, D. (2004) Oral GPIIb/IIIa antagonists: what went wrong? Curr. Pharm. Des. 10, 1587-1596
27. Desgrosellier, J.S. and Cheresh, D.A. (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22
28. Nakamura, I. et al. (2007) Involvement of alpha(v)beta3 integrins in osteoclast function. J. Bone Miner. Metab. 25, 337-344
29. Robinson, S.D. and Hodivala-Dilke, K.M. (2011) The role of beta3-integrins in tumor angiogenesis: context is everything. Curr. Opin. Cell Biol. 23, 630-637
30. Wilder, R.L. (2002) Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. 61 (Suppl. 2), ii96-ii99
31. Friedlander, M. et al. (1996) Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. U.S.A. 93, 9764-9769
32. Hersey, P. et al. (2010) A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer 116, 1526-1534
33. Murphy, M.G. et al. (2005) Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 90, 2022-2028
34. Karpusas, M. et al. (2003) Crystal structure of the alpha1beta1 integrin I domain in complex with an antibody Fab fragment. J. Mol. Biol. 327, 1031-1041
35. Hashmi, S. and Marinkovich, M.P. (2011) Molecular organization of the basement membrane zone. Clin. Dermatol. 29, 398-411
36. Giancotti, F.G. (2007) Targeting integrin beta4 for cancer and anti-angiogenic therapy. Trends Pharmacol. Sci. 28, 506-511
37. Kisker, O. (2008) Integrins: targets for anti-angiogenic therapy. In Tumor Angiogenesis: Basic Mechanisms and Cancer Therapy (Marme, D. and Fusenig, N.E., eds), pp. 761-777, Springer
38. Mas-Moruno, C. et al. (2010) Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med. Chem. 10, 753-768
39. Bell-McGuinn, K.M. et al. (2011) A phase II, single-arm study of the anti-alpha5beta1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol. Oncol. 121, 273-279
40. Almokadem, S. and Belani, C.P. (2012) Volociximab in cancer. Expert Opin. Biol. Ther. 12, 251-257
41. Barkan, D. and Chambers, A.F. (2011) Beta1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin. Cancer Res. 17, 7219-7223
42. Van Aarsen, L.A. et al. (2008) Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res. 68, 561-570
43. Rosenthal, M.A. et al. (2010) Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(v)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases. Asia Pac. J. Clin. Oncol. 6, 42-48
44. Reardon, D.A. et al. (2011) Cilengitide: an RGD pentapeptide alphavbeta3 and alphavbeta5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 7, 339-354
45. Friess, H. et al. (2006) A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6, 285
46. Kim, K.B. et al. (2007) A randomized phase II study of EMD 121974 in patients (pts) with metastatic melanoma (MM). J. Clin. Oncol. 25 (Suppl. 18S), Abstract 8548
47. Nabors, L.B. et al. (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J. Clin. Oncol. 25, 1651-1657
48. Stupp, R. et al. (2010) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 2712-2718
49. Tabatabai, G. et al. (2010) Targeting integrins in malignant glioma. Target Oncol. 5, 175-181
50. Stoeltzing, O. et al. (2003) Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer 104, 496-503
51. Mitjans, F. et al. (2000) In vivo therapy of malignant melanoma by means of antagonists of alpha v integrins. Int. J. Cancer 87, 716-723
52. O'Day, S. et al. (2011) A randomised, phase II study of intetumumab, an anti-av-integrin mAb, alone and with dacarbazine in stage IV melanoma. Br. J. Cancer 105, 346-352
53. Wirth, M. et al. (2012) Final analysis: a multicenter phase I study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody to human av integrins, in progressive castrate-resistant prostate cancer with bone metastases after chemotherapy. J. Clin. Oncol. 30 (Suppl. 5), Abstract 231
54. 18F]galacto-RGD positron emission tomography. Neuro. Oncol. 11, 861-870
55. Beer, A.J. and Schwaiger, M. (2011) PET imaging of alphavbeta3 expression in cancer patients. Methods Mol. Biol. 680, 183-200
56. Schottelius, M. et al. (2009) Ligands for mapping alphavbeta3-integrin expression in vivo. Acc. Chem. Res. 42, 969-980
57. 99mTc-NC100692. J. Nucl. Med. Meeting Abstracts 47, 175P
58. 18F-labeled alphaVbeta3-integrin and alphaV beta5-integrin imaging agent. J. Nucl. Med. 52, 424-430
59. Taga, T. et al. (2002) Alpha v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin. Int. J. Cancer 98, 690-697
60. Mikkelsen, T. et al. (2009) Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int. J. Cancer 124, 2719-2727
61. Coller, B.S. (1985) A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J. Clin. Invest. 76, 101-108
62. Scarborough, R.M. et al. (1993) Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem. 268, 1066-1073
63. Sagi, K. et al. Ajinomoto Co. Inc. Novel phenylalanine derivatives, WO2003070709
64. Tilg, H. and Kaser, A. (2010) Vedolizumab, a humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr. Opin. Investig. Drugs. 11, 1295-1304
65. Giugliano, R.P. et al. (2000) First report of an intravenous and oral glycoprotein IIb/IIIa inhibitor (RPR 109891) in patients with recent acute coronary syndromes: results of the TIMI 15A and 15B trials. Am. Heart J. 140, 81-93
66. Smith, E.E. et al. (2006) Risk factors for stroke after acute coronary syndromes in the Orbofiban in Patients with Unstable Coronary Syndromes - Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am. Heart J. 151, 338-344
67. Diamant, Z. et al. (2005) Effect of a very late antigen-4 receptor antagonist on allergen-induced airway responses and inflammation in asthma. Clin. Exp. Allergy 35, 1080-1087
68. Koga, Y. and Kainoh, M. (2010) PP-065-15 Effect of an orally active small molecule alpha4beta1/alpha4beta7 integrin antagonist, TRK-170, on experimental colitis in mice. Int. Immunol. Meeting Abstracts 22, iii138
69. Miller, D.H. et al. (2012) Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 11, 131-139
70. Hijazi, Y. et al. (2006) Evaluation of the effect of multiple-dose administration of R411, a dual alpha4beta1-alpha4beta7 integrin antagonist on the major CYP isoform activities in healthy volunteers. Eur. J. Clin. Pharmacol. 62, 83-85
71. Kapustay, P.M. et al. AIDS Research LLC. LFA-1 alpha-subunit antibodies and methods of use, US 6,919.077 B2
72. Greenberg, H.E. et al. (2000) Antiplatelet effects of MK-852, a platelet fibrinogen receptor antagonist, in healthy volunteers. J. Clin. Pharmacol. 40, 496-507
73. Mackel, J.M. et al. Allegro Pharmaceuticals, Inc. Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to RGD binding sites, PCT/US2010/056277